Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.69 |
| ▸ | CHRM3 known ✓ | P20309 | 18/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13805520 | 0.88 | CHRM2 (0.70) | CHRM2CHRM1CHRM3KCNH2 | |
| Bromide SCHEMBL4232753 | 0.88 | CHRM2 (0.70) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL13805485 | 0.86 | CHRM2 (0.86) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL12725449 | 0.85 | CHRM3 (0.68) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL12725444 | 0.84 | CHRM3 (0.80) | CHRM2CHRM1CHRM3KCNH2 | |
| Bromide SCHEMBL4219549 | 0.84 | CHRM3 (0.79) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232287 | 0.82 | CHRM2 (0.87) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232285 | 0.80 | CHRM2 (0.84) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL13805445 | 0.79 | CHRM2 (0.82) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL13805462 | 0.79 | CHRM2 (0.94) | CHRM2CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | US | claimed |
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| EP-1827439-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006055503-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM2 2/4885CHRM3 1/4885CHRM1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.